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Abstract
Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to
both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and
antiestrogenic compounds are very promising drugs for the treatment of MM. Indeed, they inhibit
cell proliferation in vitro. They block cell cycle and/or induce apoptosis even in drug-resistant MM
cells but not normal B cells. They interfere with survival pathways often deregulated in myelomas.
They co-operate with conventional drugs to enhance apoptosis or to overcome resistance. In vivo,
they act also on tumoral angiogenesis in xenograft models. As a whole, they possess all the criteria
which render them attractive for a new therapeutic strategy. Importantly, they are well-tolerated
at the doses tested in vitro or in vivo, encouraging the rapid onset of critical trials.
Review
Introduction
Multiple myeloma (MM) is still an incurable malignancy
characterized by the accumulation of tumoral plasma cells
in the bone marrow. This accumulation of myeloma cells
results in the overproduction of monoclonal immu-
noglobulins and bone destruction, two clinical features of
the disease [1]. Malignant plasma cells and bone marrow
stromal cells establish multiple interactions through
adhesion molecules and growth factors which both acti-
vate complex signaling pathways that sustain survival of
malignant cells, mediate tumor progression and drug
resistance [2]. Thus, to be effective in MM, therapeutic
agents must target both myeloma cells and bone marrow
environment. 2-methoxyestradiol (2ME2) is a natural
metabolite of estradiol with recognized antiangiogenic
and antitumor properties. These two properties are also
shared by antiestrogenic compounds belonging to either
selective estrogen receptor disruptor (SERD) or selective
estrogen receptor modulator (SERM) types. 2ME2 as well
as SERMs and SERDs have been shown potent inducers of
apoptosis in MM cells both in vitro and in vivo. This brief
review focuses on preclinical studies of 2ME2, SERD and
SERM actions and discusses the benefit of such com-
pounds in a therapeutic perspective.
Effects of 2ME2 in MM
2ME2 is a natural metabolite of estradiol (Figure 1A)
which possesses antitumoral and antiangiogenic activities
on a wide spectrum of solid tumors and leukemias [3].
2ME2 inhibits cell proliferation and induces apoptosis of
MM cell lines, MM primary cells and engrafted tumors in
immunodeficient mice [4,5]. In vitro, 2ME2, at micromo-
lar concentrations (10–50 µM), has a selective activity on
malignant MM cells since it displays no effects on normal
B lymphocytes [4]. 2ME2 induces a G2-M phase arrest and
triggers a mitochondrial-dependent cell death through the
cytosolic release of cytochrome c and Smac and in turn,
the activation of caspase-9 and thereafter, the activation of
the executioner caspase-3 [4]. In vivo, 2ME2 or 2ME2-
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loaded liposomes affect xenograft tumors growth [4,5]
and 2ME2 reduces significantly intratumoral microvessel
density [4]. Microarray analyses identified genes modu-
lated by 2ME2 and among them, genes regulating cell
death/repair machineries, genes involved in the unfolded
protein response or in the endoplasmic reticulum stress
response, genes regulating proliferation/adhesion path-
ways and structural genes [6]. The same study demon-
strated also that 2ME2 down-regulates c-Myc and targets
p27Kip1 which is cleaved to achieve its effects.
Effects of estradiol in MM
The effects of 17-β-estradiol (E2, Figure 1A) on MM cells
are less clear and data from the literature are more or less
controversial. It has been shown that E2, also at micromo-
lar concentrations, abolishes interleukin (IL)-6-depend-
ent MM proliferation, an effect which is reversed by the
estrogen receptor (ER) pure antagonist: ICI 182,780 (ICI).
Indeed, E2/ER complexes induce the expression of PIAS3
(protein inhibitor of activated STAT3), one inhibitor of
activated STAT3 (signal transducer and activator of tran-
scription 3) at the transcriptional level [7]. IL-6, which
plays a major role in the physiopathology of MM, regu-
lates both cell survival and proliferation through the
STAT3 pathway which is often constitutively activated in
MM cells [2]. Inhibition of the STAT3 pathway induces
MM cell apoptosis in vitro [8,9]. In that sense, STAT3 can
be envisaged as a prime target for therapeutic interven-
tion. Otsuki, his coworkers and us noted an inhibition of
cell proliferation of most (but not all) MM cell lines in the
presence of E2 [10,11] and a further inhibition of prolif-
eration after AE treatment in the presence of E2 [10]. By
contrast, the data of Treon and colleagues do not support
such a role. Indeed, in their study, E2-treatment has no
effect on MM cell lines [12]. The results of the different
teams are reported in Table 1. It appears that the response
to E2 could be cell-specific. Two interpretations are possi-
ble: a) in MM cells, the response to E2 is ER-dependent
and some cells such as Karpas 620, OPM-2 or ARH-77 do
not express functional ER and/or associated transcription
cofactors; b) the response to E2 is ER-independent and
E2-resistant cells lack signalization molecules engaged in
the survival, proliferation or apoptosis pathways neces-
sary for growth inhibition. Two cell lines U266 and RPMI
8226 behave differently according to the study; both are
ancient, established cell lines which could have derived in
cultures and could be no longer identical within the vari-
ous places. Moreover, the techniques used for establishing
inhibition of proliferation are quite different in the vari-
ous studies (Table 1).
Table 1: Effects of E2 on proliferation of MM cell lines*
MM cell line Response Reference
ANBL6 Inhibition [7]
ARH-77 No effect [12]
KAS-6/1 Inhibition [7]
KMM-1 Inhibition [10]
LP-1 Inhibition [11]
MM.1S/R No effect [4]
NCI-H929 Inhibition [11]
OCI-My5 No effect [12]
OPM-2 No effect [11]
RPMI 8226 No effect [4]
Inhibition [10]
Inhibition [11]
No effect [12]
U266 Inhibition [10]
Inhibition [11]
No effect [12]
* Are presented in this table only authenticated MM (or at least well-
characterized) cell lines indexed in [49]. In all cases, MM cell lines 
were treated in vitro with micromolar concentrations of E2 varying 
from 0.5 µM to 50 µM; various techniques were used to quantify cell 
proliferation: [3H]-thymidine incorporation, MTS reduction assay, cell 
number counting after trypan blue exclusion.
Chemical structures of estrogenic and antiestrogenic mole- cules Figure 1
Chemical structures of estrogenic and antiestrogenic 
molecules. Chemical structures were obtained from 
PubChem Compound 47.
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Activities of SERMs in MM
SERMs comprise triphenylethylene compounds such as
tamoxifene (Nolvadex) or toremifene (Fareston), benzo-
thiophen derivatives such as raloxifene (Evista) and a
small group of benzopyran derivatives (Figure 1B). They
are therapeutic agents used for the prevention and the
treatment of diseases such as osteoporosis (raloxifene)
and breast cancers (tamoxifene, toremifene) [13]. In MM
cells, they display a potent antiproliferative effect.
Tamoxifene and its active metabolite 4-hydroxyta-
moxifene (4HT), inhibit MM cell proliferation [10,12,14]
by blocking cells at the G1 phase [11] and by inducing
apoptosis [11,12]. MM cell lines and primary cells are sen-
sitive to this treatment. Importantly, the apoptosis of cells
isolated from MM patients is obtained with concentra-
tions of tamoxifene which do not alter the in vitro differ-
entiation of hematopoietic progenitors into myeloid and
erythroid lineages [12]. Toremifene exhibits the same bio-
logical activity although it seems less potent [10,11].
Raloxifene has also an antimyeloma activity through an
arrest of the cell cycle at the S or G2/M phases depending
on the cell line tested and the induction of a caspase-9/-8-
dependent apoptosis [14]. Interestingly, microarray anal-
yses showed that raloxifene treatment decreases the
expression of genes involved in cell survival (including c-
Myc) and induces the expression of genes regulating cell
cycle [14]. In good agreement with that, we have reported
that the effects of 4HT are mediated by a rapid (2–6 h
post-treatment) down-regulation of c-Myc [11]. The
effects of SERMs in xenograft models have not been
reported so far.
Activities of SERDs in MM
SERDs are also called pure antiestrogens since they have
antiestrogenic effects in a majority of tissues even in the
absence of estradiol. Most of them possess a steroidal
backbone and act as estrogen inhibitors (Figure 1C). ICI,
known as Faslodex, is used in the treatment of advanced
breast cancers with tamoxifene-acquired resistance [15].
ICI induces an inhibition of MM cell proliferation
although smaller than that induced by SERMs [12] (Gau-
duchon et al, submitted). RU 58 886 (RU) also a promis-
ing therapeutic agent for breast cancers [15] has the same
antimyeloma activity (Gauduchon et al, submitted). RU-
mediated inhibition of proliferation occurs through two
independent processes: cell cycle arrest at the G1 phase
and induction of mitochondrial- and endoplasmic reticu-
lum-dependent apoptosis. We have found that c-Myc is
the primary target of RU in MM cells and that the comple-
tion of apoptosis necessitates the cleavage of p27Kip1
(Gauduchon et al, submitted). In vivo, RU-loaded lipo-
somes impair engrafted tumor cells growth. In fact, an
enhanced apoptotic process occurs in RU-treated animals,
an apoptosis mediated by the mitochondrial intrinsic
death pathway. Besides proapoptotic properties, RU is
also capable of reducing tumor vasculature [16]. Indeed,
in mice bearing RPMI 8226 tumors, stealth RU-loaded
liposomes weekly injected i.v. accumulate at the vicinity
of the microvessels surrounding the tumor. A high RU
concentration is obtained locally due to AE release from
the liposomes. After endocytosis of the liposomes or pas-
sive diffusion, RU has two effects within the cells: it blocks
the production of VEGF (vascular endothelial growth fac-
tor) by MM cells and inhibits VEGF secretion by endothe-
lial cells [16]. Those combined effects of encapsulated
SERM and SERD on both tumoral cells and tumoral envi-
ronment have been previously described in a xenograft
model of breast cancer tumor [17].
Are ER needed for MM response towards 
estrogenic or antiestrogenic compounds?
As summarized Table 2, 2ME2, SERDs and SERMs seem
very potent in MM cell lines, inducing cell cycle arrest
and/or apoptosis both leading to the inhibition of prolif-
eration. The biological effects of estrogens are principally
mediated by two types of receptors, namely ERα and ERβ
which possess similar structures but distinct functions
[18]. MM cell lines and primary cells express ERα and ERβ
mRNAs [10] and proteins although with various levels
[7,10,11,14,19,20] (Table 3). The relative level of each
form remains unknown essentially because of the poor
quality of most available antibodies and the variability of
such antibodies among the studies. This point is very
important to resolve since ERβ could be a physiological
dominant negative form of ERα and the ERα/ERβ ratio
may regulate the response to E2. Indeed, it has been
reported that in mature B cells, and in B tumoral cells
including LP-1 cell line, ERβ is abundant whereas ERα is
not detectable [20]. MM cells may express predominantly
ERβ form and be growth-inhibited by E2. A comparative
analysis of the response of cells to E2 and the expression
of ER types does not clarify further this point (see Tables
1 and 3). Interestingly, at high concentration (~10 µM),
E2 inhibits cell proliferation and induces apoptosis of
breast cancer cells suggesting a common mechanism of
action [21]. Furthermore, ERβ inhibits angiogenesis and
growth of breast cancer xenografts [22]. The emerging
hypothesis is that, in MM cells, E2 may signal through
ERβ to inhibit cell proliferation in vitro and in vivo.
The necessity of ER for the antiproliferative response to
2ME2 has been ruled out in breast cancer cells [21]. 2ME2
binds poorly to ERs, is not agonistic for ERs and its anti-
proliferative activity is mediated independently of both
forms. These findings coupled to other studies suggest
that 2ME2-mediated effects on MM cells are independent
of ERs [4].
The question of ERs mediating the AE response in MM
cells is still open. Karpas 620 cells, which do not expressMolecular Cancer 2007, 6:59 http://www.molecular-cancer.com/content/6/1/59
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Table 2: Response of MM cell lines towards various treatments
Cell lines Compounds Ref.
2ME2 Tam 4HT Tor Ral ICI RU
ANBL6 CCA + Ap.* [5]
Karpas 620 No [11]
No **
KAS-6/1 CCA + Ap. [5]
KMM-1 CCA + Ap. CCA + Ap. [10]
LP-1 CCA + Ap. [11]
CCA CCA **
MM.1S/R Ap. [4]
NCI-H929 CCA + Ap. [11]
Ap. Ap. **
OCI-My5 CCA + Ap. [4]
CCA + Ap. [5]
OPM-2 No [11]
CCA CCA **
RPMI 8226 Ap. [4]
CCA [5]
CCA + Ap. [11]
CCA + Ap. CCA + Ap. No CCA + Ap. [12]
CCA + Ap. CCA + Ap. [13]
Ap. Ap. **
U266 CCA + Ap. CCA + Ap. [10]
CCA + Ap. [11]
CCA + Ap. CCA + Ap. CCA + Ap. [12]
CCA + Ap. CCA + Ap. [14]
No No **
Presented cell lines were chosen as in Table 1. Cell lines were treated in vitro with micromolar concentrations of 2ME2, SERMs or SERDs (0.5–50 
µM) and drug effects were detected 24–72 h later. Cell cycle arrest was demonstrated essentially by flow cytometry sorting of propidium iodide-
stained cells, apoptosis was assessed with different techniques such as annexin V staining, caspase activity assays, mitochondrial membrane potential 
measurement, and TUNEL method. * CCA, cell cycle arrest; Ap., apoptosis; Tam, tamoxifene; Tor, toremifene, Ral, raloxifene. ** Gauduchon et al, 
submitted.
Table 3: Expression of ERα and ERβ on MM cell lines
Cell line ERα Antibody ERβ Antibody Reference
ANBL6 +++ nd, Upstate - nd, Upstate [7]
Karpas 620 - D12, Santa Cruz - G Greene, E82 [19]
- J-C Faye [11]
KAS-6/1 +++ nd, Upstate + nd, Upstate [7]
LP-1 - D12, Santa Cruz + J-C Faye [11]
- D12, Santa Cruz + G Greene, E82 [19]
- HC-20, Santa Cruz +++ 503 [18]
+ 1D5, Dako [18]
NCI-H929 +++ D12, Santa Cruz + J-C Faye [11]
OCI-My5 - TE1115011 [12]
OPM-2 + D12, Santa Cruz + J-C Faye [11]
RPMI 8226 + D12, Santa Cruz + J-C Faye [11]
+++ HC-20, Santa Cruz +++ H-150, Santa Cruz [14]
+ TE1115011 [12]
U266 +++ HC-20, Santa Cruz + G Greene, E82 [19]
+ J-C Faye [11]
+++ TE1115011, nd [12]
Presented cell lines were chosen as in Table 1. Proteins were purified from cultured MM cell lines, separated by SDS-PAGE and immunoblotted 
with the indicated antibodies according to conventional methods. +++, high expression; +, weak expression; -, no expression; nd, not described.Molecular Cancer 2007, 6:59 http://www.molecular-cancer.com/content/6/1/59
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any ER isoforms, are completely resistant to 4HT [11].
When transfected with expression plasmids coding for
ERα or ERβ, and then treated with 4HT, Karpas 620 cells
exhibit a weak but significant decrease of cell proliferation
[11]. This result indicates that ERα and ERβ restaure at
least partially the response to 4HT. OPM-2 cells although
expressing moderately both ERα and ERβ, appear sensi-
tive to ICI and RU but resistant to 4HT. The opposite is
also true, U266 highly expressing ERα, is resistant to ICI
and RU but 4HT-responsive [11] (Gauduchon et al, sub-
mitted). OCI-My5 cells which are ERα-negative are
growth-inhibited after 2ME2 [4] and Tam [5] treatments.
Altogether, these results indicate that ERα or ERβ may
contribute but only partially to the response against AEs.
Moreover, the presence or the absence of a specific ER
form cannot be correlated to a particular response to
estrogenic or antiestrogenic compounds (see Tables 2 and
3).
The effects of SERMs and SERDs on breast cancer cells
resemble the effects on MM cells. Indeed, in vitro concen-
trations of SERMs and SERDs necessary to achieve the bio-
logical response are close to 10 µM [23,24]. Moreover, ICI
and tamoxifene, have been shown to induce a rapid cell
death in MDA-MB-231 ER-negative breast cancer cells,
like in ER-positive MCF-7 cells [25]. Tamoxifene- or ICI-
induced breast cancer cells apoptosis is associated with
the increase of tumor necrosis factor receptor 1 (TNFR1)
[26], the activation of caspase-3 and c-jun NH2-terminal
kinase-1 (JNK) [25] or the extracellular signal-regulated
kinase (ERK) [27] signaling pathways, or an increase in
the production of oxygen reactive species [28]. Tamoxifen
and ICI, although being strong affinity ligands for ERs, act
on the viability of ER-positive and -negative cells via mul-
tiple signaling pathways. The same multiple signaling
pathways could be implicated in MM cells.
E2 as well as AEs may induce a cellular response through
non genomic signals mediated by membrane-associated
ERs [29]. Several works have demonstrated the membrane
localization of ERα in MCF-7 cells and other cell types
[30-32]. Such localization may explain the rapid effect of
E2 and AE on ERK and their subsequent actions [27].
Today, no data support a membrane localization of ERβ.
Interestingly also, a raft-located estrogen receptor-like
protein, distinct from ERα, insensitive to ICI, has been
characterized [33]. Thus, it is possible that the effects of
estrogen in many cells and that of AEs in MM cells are
mediated by a still unknown receptor.
How 2ME2, SERMs and SERDs signal to arrest 
the cell cycle and to trigger apoptosis?
2ME2 and SERMs/SERDs compounds inhibit MM cell
proliferation mainly by two distinct and independent
ways: they arrest cell cycle and they induce apoptosis. It
appears that all these compounds although structurally,
biologically different signal through the same pathways.
The first common target of 2ME2, raloxifene, 4HT and RU
is the proto-oncogene c-Myc which is involved in the con-
trol of proliferation [6,11,14] (Gauduchon et al, submit-
ted). c-Myc control the expression of G1 transition genes
and inhibiting c-Myc halts tumor cell proliferation [34].
This is the precisely the biological activity of ICI and
tamoxifen in breast cancer cells, they downregulate c-Myc
and induce cell cycle arrest through the induction of the
two cell cycle inhibitors p21Cip1 or p27Kip1 (Figure 2) [35-
38]. Following the downregulation of c-Myc in 4HT- or
raloxifene-treated MM cells, we and others observed the
up-regulation and redistribution of p21Cip1 and p27Kip1
leading to cell cycle arrest [11,14]. Interestingly, p27Kip1 is
degraded and cleaved by a protease in 2ME2-induced
apoptotic MM cells [6] that we identified as a caspase in
RU-treated cells (Gauduchon et al, submitted). The apop-
tosis is triggered by the mitochondrial intrinsic death
pathway by AE (Figure 3) again in close similarity with
that observed in breast cancer cells [39]. Importantly, also,
SERMs could interfere with survival pathways known to
be constitutively activated in MM such as Janus Kinase
(JaK)/STAT3 [40,41], NF-κB (nuclear factor-κB) [42,43]
and Ras/MAPK (mitogen-activated protein kinase)
[44,45]. For example, raloxifene blocks the NF-κB activity
through a modulation of the ER association with the p65
subunit [14]. We have some preliminary data which indi-
Schematic representation of AEs signaling in breast cancer  and myeloma cells Figure 2
Schematic representation of AEs signaling in breast 
cancer and myeloma cells. In breast cancer cells, ICI and 
tamoxifene (Tam) both downregulate c-Myc and its target 
cyclin D1 [35, 39]. But depending on the treatment, there is 
either an upregulation of p21Cip1 or p27Kip1 and thereafter the 
inhibition of cyclin E/CDK2 activity and the arrest in G0 for 
ICI or G1 for Tam [36]. In MM cells, 4HT and RU treatments 
induce a rapid downregulation of c-Myc, an upregulation of 
p27Kip1 and the subsequent decrease activity of cyclin D/CDK 
leading to a G1-arrest in [11] (Gauduchon et al, submitted).
Breast cancer cells
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cate that RU is capable of inhibiting the JAK/STAT3 but
not the Pi3K (phosphoinositol 3-kinase)/AKt pathway
(Seguin et al, unpublished).
However, we did not find any cross-talk between ER and
STAT3 in RU-treated MM cells. In fact, we think that in the
cellular model used by Wang and coworkers, the STAT3
pathway is functional [7]. This is not true for the MM cell
lines used in our study (they all display a constitutively
activated STAT3) and for MM patients in which STAT3 is
also constitutively activated [40,41].
Conclusion
To conclude, 2ME2 and SERMs (which seem more effi-
cient than SERDs) are able to block MM cell cycle arrest,
to trigger the intrinsic death pathway, to inhibit one or
several survival pathways. These properties are necessary
both to limit MM cell proliferation and to overcome
resistance towards conventional or more novel drugs.
Indeed, most of these compounds are able to synergize
with dexamethasone, doxorubicin, bortezomib, arsenic
trioxide to achieve cell growth inhibition [5,11,13] (Gau-
duchon et al, submitted). Moreover they are well-toler-
ated; and encouraging preliminary results have been
reported on MM patients receiving tamoxifene [46].
Finally, 2ME2, SERMs/SERDs target the tumoral microen-
vironment and in particular inhibit the synthesis of ang-
iogenic factor(s); all these properties provide a rationale
for clinical studies.
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